Its an indirect effect, but it makes sense from a physiological perspective
Triple-hormone-receptor agonist Retatrutide for obesity: Phase 2 trial (48-week study, up to 24% weight loss) American Diabetes Association (2023) ADA Press Release: Novel agent Retatrutide results in substantial weight reduction (83rd Scientific Sessions, Phase 2 data) ADA Meeting News (2023) Phase 2 trial results: benefits of Retatrutide in obesity, type 2 diabetes, NASH (83rd ADA Scientific Sessions coverage) ClinicalTrials.gov Study of Retatrutide (LY3437943) in adults with obesity (NCT04881760
Track mood daily alongside dose changes, medication timing, sleep, stress, and food intake
Gastroparesis is a digestive condition in which the stomach takes an abnormally long time to empty its contents
Supports Collagen Production: By boosting collagen levels, the tablet helps maintain skin elasticity and firmness, which can contribute to a more youthful appearance
Carlsson A, Lindqvist M, Magnusson T
